AACR 2024 | Evolving biomarker driven therapies to overcome gastric cancer tumor resistance

Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, summarizes a session focusing on molecular drivers of gastroesophageal cancers, and advances in biomarker driven therapies for patients with gastroesophageal cancers. Emerging data suggests that over 70% of HER2 positive tumors possess TP53 mutations, and this data indicates a balance between the type of TP53 mutation and the fitness trade-off between HER2, copy number alteration, and P53. Dr Janjigian has led research primarily focused on mechanisms of intrinsic and acquired resistance, with the aim to develop effective therapeutic strategies to overcome resistance and target HER2 in gastric cancers. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.